February 19th, 2025 | 08:00 CET
Pharma in Focus: Bayer, BioNxt Solutions, Novo Nordisk – Market Expansion, Innovation Acceleration, and a Costly Breach of Trust
The pharmaceutical and biotech market is on the move. Bayer AG aims to win the hearts of 1.2 million Japanese patients suffering from heart failure with promising study data. A drug that has already been successful in 90 countries is to be given an additional benefit. The biotech company BioNxt Solutions is attracting attention with new personnel in the finance and business areas. Its innovative drug delivery solutions could significantly improve the quality of life for millions of patients with neurodegenerative or chronic diseases. The move to a state-of-the-art research facility could accelerate the development of the active ingredients in its pipeline. Unfortunately, Novo Nordisk faces a setback following an M&A: the billion-dollar acquisition of an antihypertensive therapy turns out to be a costly mistake.
time to read: 4 minutes
|
Author:
Juliane Zielonka
ISIN:
BAYER AG NA O.N. | DE000BAY0017 , Bionxt Solutions Inc. | CA0909741062 , NOVO NORDISK A/S | DK0062498333
Table of contents:
Author
Juliane Zielonka
Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.
Tag cloud
Shares cloud
Bayer applies for approval of new heart failure drug in Japan
The pharmaceutical division of Bayer AG has applied to the Japanese Ministry of Health, Labor and Welfare for approval of the drug finerenone. It is intended for the treatment of patients with chronic heart failure (HF) diagnosed with LVEF ≥40%. LVEF stands for "Left Ventricular Ejection Fraction" and is a crucial measurement of heart function. These patients currently have limited treatment options.
The drug finerenone is currently only approved for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes in over 90 countries. Now, it is to be added to the list of indications in the land of the rising sun, specifically for the treatment of HF. There are around 1.2 million heart failure patients in Japan with this exact LVEF of ≥40%. Based on the positive results of the Phase III FINE ARTS-HF study, approval is expected to be granted quickly.
Executive Vice President Christine Roth emphasizes the importance of this development: "While physicians have to take into account the complexity of numerous comorbidities, they have few clinically proven treatment options at their disposal." This could change following a successful approval of finerenone for this indication. Japan is known for its ageing population, so this particular condition could progress there in the next few years.
BioNxt Solutions strengthens management team and research site
The innovative biotech company BioNxt Solutions is taking two strategically valuable steps to strengthen its market position at the beginning of the year. With David Waterhouse, the management is bringing an experienced business expert with over twelve years of experience in entrepreneurship and consulting onto the board. Waterhouse holds a Bachelor of Science in Biological Sciences from the University of Edinburgh, UK. His business expertise is particularly in the areas of business development, financial strategy, and capital raising.
Waterhouse has good relations with US state and federal agencies. These connections can offer a significant advantage for the US market, where the projected volume for the neurodegenerative disease Multiple Sclerosis is expected to reach USD 46.44 billion by 2032, creating a lucrative market. In the pipeline of BioNxt Solutions, there are additional therapeutics under development for neurodegenerative and chronic diseases, which, through unique drug delivery, can help many patients to an improved quality of life.
One of the challenges for patients with MS or a comparable disease is the prescription drugs that are often taken over the long term and can cause unpleasant side effects, including organ damage. BioNxt Solutions offers two approaches:
A soluble extra-thin patch that dissolves under the tongue with the active ingredient, allowing the therapeutic agent to enter the bloodstream much faster through the oral mucosa. This protects the gastrointestinal tract and liver metabolism.
Skin patches that allow for continuous release of the active ingredient when worn on the body. This can also reduce side effects and the risk of forgetting to take medication.
On March 1, 2025, the Company will move to the Munich-based contract development laboratory Gen-Plus. The research facility, with over 1000 sqm of space, will particularly accelerate the development of the lead product candidate BNT23001.
Novo Nordisk is claiming millions in damages from KBP Biosciences
Novo Nordisk is seeking damages of up to USD 830 million from KBP Biosciences, according to Reuters. The reason is an alleged fraud during the purchase of an anti-hypertensive drug in 2023.
On behalf of Novo Nordisk, a Singapore court has issued a worldwide asset freeze against KBP and its founder, Huang Zhenhua. According to New York law, there is reasonable suspicion of fraud. The Danes paid around USD 1.3 billion for the drug ocedurenone, which is used to treat high blood pressure in patients with chronic kidney disease, in October 2023. After unfavorable clinical trial results became known, Novo Nordisk had to post a loss of approximately USD 800 million.**
KBP is said to have knowingly withheld valuable information – including analyses of study results showing the ineffectiveness of ocedurenone. As a next step, Novo Nordisk will now initiate arbitration proceedings in New York, USA.
Bayer AG's pharmaceutical division is showing a promising growth candidate with the filing of finerenone in Japan. The potential expansion of the indication for heart failure could tap into a market of 1.2 million affected individuals in Japan. The positive results of the Phase III FINEARTS-HF study are an important asset in the approval process. The biotech company BioNxt Solutions is taking two significant strategic steps for future growth. David Waterhouse brings valuable expertise in business development and US market access to the team and the board of directors. The innovative drug delivery technology offers promising potential for patients with chronic diseases. The move to the Munich-based development laboratory Gen-Plus may also favor an acceleration of product development. Novo Nordisk is taking legal action against KBP. The Danish pharmaceutical company aimed to secure another market in the field of cardiovascular diseases through the acquisition. However, the drug candidate turned out to be a flop due to the horrific study results. The loss of USD 800 million after the USD 1.3 billion deal illustrates how thoroughly work needs to be done in the pharmaceutical industry, especially in the area of M&A. Active investors can seize a great opportunity to explore not only pharmaceutical and biotech companies but also other players at the 14th International Investment Forum, which will take place online on February 25, 2025. Register here for free.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
